FindMyKOL

Adam Widman

Basic profile

Medical Oncology

ORCIDNone on fileNPI↗
RegionMiddletown, NJ · NortheastSpecialtyMedical OncologyFocusOncology
Active KOLFindMyKOL typeFindMyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Adam Widman is an Oncology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    75%
    Aromatase Inhibitor60.7%
    Letrozole87%Anastrozole13%
    Part D<11 patients
    Estrogen Agonist/Antagonist14.3%
    Tamoxifen Citrate100%
    Part D<11 patients
  • Cardiovascular

    16.7%
    Arteriolar Vasodilator8.9%
    Minoxidil100%
    Part D<11 patients
    Loop diuretic7.7%
    Furosemide100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    8.3%
    Serotonin-3 Receptor Antagonist8.3%
    Ondansetron Hcl100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”